Business
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to
About this update from Eyepoint, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 52nd Annual Retina Society Scientific Meeting being held September 11-15, 2019 in London.\n “The U.S. commercial launch of YUTIQ has received strong support and reception from uveitis specialists,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “Physicians continue to cite the durable, 36-month follow up Phase 3 data of YUTIQ as an innovative advance to the current treatment options due to its long-lasting activity and convenient, consistent dosing. We believe YUTIQ is well-positioned to address the treatment limitations and unmet need associated with chronic, non-infectious uveitis affecting the posterior segment of the eye and anticipate increasing penetration within this historically underserved patient community.” Details for the Retina Society presentations are as follows: Title: The Use of Adjunctive Anti-inflammatory Medications: Results from a 3 Year Study of a Fluocinolone Acetonide Intravitreal Insert in Chronic Non-Infectious Uveitis Affecting the Posterior SegmentPresenter: Dilraj Grewal, M.D., Associate Professor of Ophthalmology, Duke Eye CenterSession Title: Inflammation Date and Time: Sunday, September 15, 2019, 11:52-11:58 AM BST Title: Minimizing Uveitic Recurrences: Results from a 36M Study of Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior SegmentPresenter: Thomas Arno Albini, M.D., Professor of Clinical Ophthalmology, Bascom Palmer Eye InstituteSession Title: Inflammation Date and Time: Sunday, September 15, 2019, 12:02-12:08 PM BST About YUTIQ® YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye, and was approved by the FDA on October 12, 2018. A link to the full product label is available on the EyePoint ...